These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 8341116)

  • 21. Hepatic and haematological adverse reactions associated with the use of multidrug therapy in leprosy--a five year retrospective study.
    Kaluarachchi SI; Fernandopulle BM; Gunawardane BP
    Indian J Lepr; 2001; 73(2):121-9. PubMed ID: 11579648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of acetylator phenotype on the haematological and biochemical effects associated with dapsone in leprosy patients.
    Queiroz RH; Souza AM; Melchior E; Gouveia EG; Carvalho D
    Lepr Rev; 1997 Sep; 68(3):212-7. PubMed ID: 9364821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multidrug therapy (MDT) and leprosy control.
    Noordeen SK
    Indian J Lepr; 1990; 62(4):448-58. PubMed ID: 2086680
    [No Abstract]   [Full Text] [Related]  

  • 24. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
    Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
    Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of MDT implementation in the Tanzania National TB-Leprosy Programme.
    Chum HJ
    Lepr Rev; 1986; 57 Suppl 3():63-6. PubMed ID: 3573963
    [No Abstract]   [Full Text] [Related]  

  • 26. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy.
    Villahermosa LG; Fajardo TT; Abalos RM; Cellona RV; Balagon MV; Dela Cruz EC; Tan EV; Walsh GP; Walsh DS
    Am J Trop Med Hyg; 2004 Feb; 70(2):197-200. PubMed ID: 14993633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A clinico-pathological study of multidrug regimen in paucibacillary leprosy.
    Kar PK; Jha PK; Panayach JS; Snehi PS
    Indian J Lepr; 1988 Apr; 60(2):235-41. PubMed ID: 3192972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results.
    Mane I; Cartel JL; Grosset JH
    Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):224-9. PubMed ID: 9251595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relapses in paucibacillary leprosy after MDT--a clinical study.
    Grugni A; Nadkarni NJ; Kini MS; Mehta VR
    Int J Lepr Other Mycobact Dis; 1990 Mar; 58(1):19-24. PubMed ID: 2319185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dapsone drug resistance in the MDT era.
    Roche PW; Neupane KD; Failbus SS; Butlin CR
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):323-5. PubMed ID: 11221097
    [No Abstract]   [Full Text] [Related]  

  • 31. [Guideline for the treatment of Hansen's disease in Japan (Second edition)].
    Goto M; Nogami R; Hatano K; Okano Y; Ishii N; Gidoh M; Ishida Y; Ozaki M;
    Nihon Hansenbyo Gakkai Zasshi; 2006 Sep; 75(3):191-226. PubMed ID: 17037376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mortality due to dapsone hypersensitivity syndrome complicating multi-drug therapy for leprosy in Nepal.
    Pandey B; Shrestha K; Lewis J; Hawksworth RA; Walker SL
    Trop Doct; 2007 Jul; 37(3):162-3. PubMed ID: 17716505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term multidrug therapy in multibacillary leprosy--review of 80 cases in two provinces of China (1983-1988).
    Li HY; Yu XL; Zhang MS; Duan CX; Huang WB; Zhang SB; Zhu K; Ma JF
    Int J Lepr Other Mycobact Dis; 1989 Sep; 57(3):622-7. PubMed ID: 2778368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Agranulocytosis induced by multidrug therapy in leprosy treatment: a case report.
    Silva IM; Oliveira CA; Guedes WR; Oliveira BB; Oliveira DA; Guedes Filho G
    Braz J Infect Dis; 2009 Apr; 13(2):158-60. PubMed ID: 20140364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Malta experience. Isoprodian-rifampicin combination treatment for leprosy.
    Depasquale G
    Lepr Rev; 1986; 57 Suppl 3():29-37. PubMed ID: 3573957
    [No Abstract]   [Full Text] [Related]  

  • 36. Dapsone syndrome in Vanuatu: a high incidence during multidrug treatment (MDT) of leprosy.
    Reeve PA; Ala J; Hall JJ
    J Trop Med Hyg; 1992 Aug; 95(4):266-70. PubMed ID: 1386634
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
    Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
    Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Drugs used in tuberculosis and leprosy].
    Aoyagi T; Toyoda T
    Nihon Rinsho; 1990 Oct; 48(10):2212-7. PubMed ID: 2280466
    [No Abstract]   [Full Text] [Related]  

  • 39. Why multidrug therapy for multibacillary leprosy can be shortened to 12 months.
    Ji B
    Lepr Rev; 1998 Jun; 69(2):106-9. PubMed ID: 9715593
    [No Abstract]   [Full Text] [Related]  

  • 40. Dapsone hypersensitivity syndrome in an adolescent during treatment during of leprosy.
    Bucaretchi F; Vicente DC; Pereira RM; Tresoldi AT
    Rev Inst Med Trop Sao Paulo; 2004; 46(6):331-4. PubMed ID: 15654479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.